@article{519ed276b65d4d78b698631f5c6707f2,
title = "Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance",
author = "K. Reich and Gordon, {K. B.} and B. Strober and Langley, {R. G.} and M. Miller and Yang, {Y. W.} and Shen, {Y. K.} and Y. You and Y. Zhu and P. Foley and A. Blauvelt",
note = "Funding Information: Kristian Reich has served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Forward Pharma, Gilead, Galderma, Janssen‐Cilag, Kyowa Kirin, Leo Pharma, Eli Lilly, Medac, Novartis, Ocean Pharma, Pfizer, Sanofi and UCB Pharma; Professor Reich is co‐founder of Moonlake Immunotherapeutics. Kenneth B. Gordon has received honoraria as a consultant for AbbVie, Almirall, Amgen, Arcutis, Arena Pharm, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Dermira, Dermavant, Eli Lilly, Incyte, Kyowa Hakko, Krin, Leo Pharma, Novartis, Pfizer, Sanofi‐Genzyme Sun and UCB Pharma and has received grants for research support from AbbVie, Bristol‐Myers Squibb, Celgene, Eli Lilly, Janssen and Novartis. Bruce Strober has received honoraria as a consultant for AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Bristol‐Myers‐Squibb, Connect Biopharma, Dermavant, Dermira, Eli Lilly, Equillium, GlaxoSmithKline, Immunic Therapeutics, Janssen, Leo Pharma, Maruho, Meiji Seika Pharma, Mindera, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi‐Genzyme, Sun Pharma, UCB Pharma, Ventyxbio and vTv Therapeutics; is a speaker for AbbVie, Eli Lilly, Janssen and Sanofi‐Genzyme; is the Co‐Scientific Director of the Cor‐Evitas (Corrona) Psoriasis Registry; is an investigator for AbbVie, Cara, Corrona Psoriasis Registry, Dermavant, Dermira and Novartis; is a shareholder for Connect Biopharma; and receives honoraria for Editor‐in‐Chief of . Richard G. Langley has received honoraria as a principal investigator, scientific advisor or speaker for AbbVie, Amgen, Boehringer Ingelheim, Bristol‐Myers‐Squibb, Dermavant, Dermira, Eli Lilly, GlaxoSmithKline, Janssen, Leo Pharma, Novartis, Ortho Dermatologics, Pfizer, Sanofi‐Genzyme, Sun Pharma and UCB Pharma. Peter Foley has received grant support from AbbVie, Amgen, Bristol‐Myers Squibb, Celgene, Eli Lilly, Galderma, Janssen, Leo Pharma, Merck, Novartis, Pfizer, Sanofi and Sun Pharma; has served as an investigator for AbbVie, Amgen, Arcutis, Aslan, AstraZeneca, Boehringer Ingelheim, Botanix, Bristol‐Myers Squibb, Celgene, Celtaxsys, CSL, Cutanea, Dermira, Eli Lilly, Evelo, Galderma, Genentech, Geneseq, GlaxoSmithKline, Hexima, Janssen, Kymab, Leo Pharma, Merck, MedImmune, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi, Sun Pharma, Teva, UCB Pharma and Valeant; has served on advisory boards for AbbVie, Amgen, Aslan, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, Janssen, Leo Pharma, Mayne Pharma, Merck, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma and Valeant; has served as a consultant for Bristol‐Myers Squibb, Eli Lilly, Galderma, GenesisCare, Hexima, Janssen, Leo Pharma, MedImmune, Novartis, Pfizer, Roche and UCB Pharma; has received travel grants from AbbVie, Eli Lilly, Galderma, Janssen, Leo Pharma, Merck, Novartis, Pfizer, Roche, Sun Pharma and Sanofi; and has served as a speaker for or received honoraria from AbbVie, Amgen, Celgene, Eli Lilly, Galderma, GlaxoSmithKline, Janssen, Leo Pharma, Merck, Novartis, Pfizer, Roche, Sanofi, Sun Pharma and Valeant. Andrew Blauvelt has served as a scientific adviser and/or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol‐Myers Squibb, Dermavant, EcoR1, Eli Lilly, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo Pharma, Novartis, Pfizer, Rapt, Regeneron, Sanofi‐Genzyme, Sun Pharma, UCB Pharma and Vibliome. Megan Miller, Yaung‐Kaung Shen, Yin You and Yaowei Zhu are employees of Janssen Research & Development, LLC, a wholly owned subsidiary of Johnson & Johnson, and own stocks in Johnson & Johnson. Ya‐Wen Yang is an employee of Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA and owns stocks in Johnson & Johnson. Journal of Psoriasis and Psoriatic Arthritis Funding Information: This work was supported by Janssen Research & Development, LLC, Spring House, PA, including funding and guidance for the conduct of the research and the preparation of the article, including the collection, analysis and interpretation of data; writing of the report; and the decision to submit the article for publication. Publisher Copyright: {\textcopyright} 2022 European Academy of Dermatology and Venereology.",
year = "2022",
month = dec,
doi = "10.1111/jdv.18474",
language = "English",
volume = "36",
pages = "2393--2400",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "12",
}
